Martin MacKay
Known title: DirectorCIK: 0001414815
Martin MacKay's purchase track record
Martin MacKay has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 1/10/2022 | RLYB | $103K | -22.9% | -24.1% | -17.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| CRL | ▲ Buy | Grant | 1,438 | $255K | 5/8/2026 | View on chart |
| CRL | ▲ Buy | Grant | 1,407 | $250K | 5/8/2026 | View on chart |
| CRL | ▲ Buy | Grant | 946 | $128K | 5/21/2025 | View on chart |
| CRL | ▲ Buy | Grant | 815 | $110K | 5/21/2025 | View on chart |
| CRL | ▲ Buy | Grant | 559 | $128K | 5/13/2024 | View on chart |
| CRL | ▲ Buy | Grant | 372 | $85K | 5/13/2024 | View on chart |
| CRL | ▲ Buy | Grant | 95 | $0 | 7/3/2023 | View on chart |
| CRL | ▲ Buy | Grant | 338 | $0 | 5/31/2023 | View on chart |
| CRL | ▲ Buy | Grant | 664 | $0 | 5/15/2023 | View on chart |
| CRL | ▲ Buy | Grant | 549 | $0 | 5/11/2022 | View on chart |
| CRL | ▲ Buy | Grant | 292 | $0 | 5/11/2022 | View on chart |
| RLYB | ▲ Buy | Open Market | 4,496 | $48K | 1/11/2022 | View on chart |
| RLYB | ▲ Buy | Open Market | 5,504 | $56K | 1/10/2022 | View on chart |
| CRL | ▲ Buy | Grant | 63 | $0 | 1/3/2022 | View on chart |
| RLYB | ▼ Sell | Other | 272,609 | — | 7/28/2021 | View on chart |
| RLYB | ▼ Sell | Other | 436,517 | — | 7/28/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
CRL Analyst Targets Rise After UBS Reinstates Coverage
Charles River Laboratories saw its average analyst price target increase to $305.00, driven by UBS reinstating coverage with a $357.00 target. This move follows reports of stabilizing demand and increased interest in animal model markets. The stock is currently trading below its 52-week high, with technical indicators showing support near $181.76.
CRL Analyst Targets Rise After UBS Reinstates Coverage. Charles River Laboratories saw its average analyst price target increase to $305.00, driven by UBS reinstating coverage with a $357.00 target. This move follows reports of stabilizing demand and increased interest in animal model markets. The stock is currently trading below its 52-week high, with technical indicators showing support near $181.76.